scispace - formally typeset
M

Michael Jarman

Researcher at Brunel University London

Publications -  119
Citations -  4343

Michael Jarman is an academic researcher from Brunel University London. The author has contributed to research in topics: Metabolite & Idoxifene. The author has an hindex of 33, co-authored 119 publications receiving 4251 citations.

Papers
More filters
Journal ArticleDOI

Hormonal impact of the 17 alpha-hydroxylase/C-17,C-20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

TL;DR: Repeated treatment of men with intact gonadal function with abiraterone acetate at a dose of 800 mg can successfully suppress testosterone levels to the castrate range, however, this level of suppression may not be sustained in all patients due to compensatory hypersecretion of LH.
Journal ArticleDOI

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

TL;DR: Compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3- pyridol)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase.
Journal ArticleDOI

Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

TL;DR: It appeared that, of the known metabolites of cyclophosphamide, only phosphoramide mustard possesses the cytoxicity and biological half-life appropriate to the active antitumour metabolite, and four other metabolites of low cytotoxicity were isolated and identified.
Journal ArticleDOI

Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.

TL;DR: A series of isothiazolone-based HAT inhibitors were identified and chemical reactivity of these compounds, as measured by covalent protein binding and loss of HAT inhibition in the presence of DTT, indicated that reaction with thiol groups might be important in their mechanism of action.
Journal ArticleDOI

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.

TL;DR: A new compound can form interstrand crosslinks in the DNA of Chinese hamster V79 cells to which it is also highly toxic, findings indicative of the formation by Walker cells of a diffusible toxic metabolite of CB 1954.